TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males, between 18 and 55 years of age, inclusive~* Body Mass Index range 18.0 to 30.0 kg/m2, inclusive~* Have NAT2 slow or rapid acetylator genotype~* In good health as determined by the investigator~* Negative test for selected drugs of abuse at screening~* Negative screens for Hepatitis B, Hepatitis C and HIV~* Sterile or agrees to use an approved method of contraception from Check-in until 45 days following Clinic Discharge~* Able to comprehend and willing to sign an Informed Consent Form~* Have 1 to 2 bowel movements per day~Exclusion Criteria:~* Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder~* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance~* History of stomach or intestinal surgery or resection~* History or presence of an abnormal ECG,~* History of clinically significant alcohol or drug use within 1 year prior to Check-in~* Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in~* Exposure to significant radiation within 12 months prior to Check-in -Use of any tobacco- or nicotine-containing within 6 months prior to Check- in~* Use of any drugs which may interact with the study drug within 30 days prior to Check-in~* Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in~* Use of any prescription medications/products within 14 days prior to Check in~* Use of any over-the-counter, non-prescription drugs within 7 days prior to Check-in~* Use of grapefruit or grapefruit-containing foods or beverages within 7 days prior to Check-in~* Use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in~* Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion~* Receipt of blood products within 2 months prior to Check-in~* Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Slow and rapid N-acetyl transferase genotypes (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AGN201781 in Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia~* Moderate or severe pain associated with postherpetic neuralgia or post-traumatic peripheral neuralgia~Exclusion Criteria:~* Women of child-bearing potential~* Any other uncontrolled diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AGN201781 (Type: EXPERIMENTAL): AGN201781 50 mg capsules three-time daily for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo 50 mg capsules three-times daily for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IC14 Antibodies to Treat Individuals With Acute Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Presence of ALI, defined as the following:~  1. Acute onset (less than 28 days from study entry)~ 2. PaO2/FiO2 of less than 300~ 3. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph (infiltrates may be patchy, diffuse, homogeneous, or asymmetric)~ 4. Requirement for positive pressure ventilation via endotracheal tube~ 5. No clinical evidence of left atrial hypertension~* Clinical indication for antimicrobial therapy at the time of randomization~* Anticipated duration of mechanical ventilation greater than 48 hours~Exclusion Criteria:~* Treatment with a drug or device within 30 days prior to study entry that has not received regulatory approval at the time of study entry~* Does not meet safety criteria for bronchoscopic alveolar lavage either at baseline or is anticipated to be too high a risk for lavage on Day 1 of the study~* Intubation for cardiopulmonary arrest~* Intubation for status asthmaticus, pulmonary embolus, or myocardia infarction~* Anticipated survival less than 48 hours from intubation~* Anticipated survival less than 28 days due to pre-existing medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Regular Physical Exercise Extends Honeymoon Phase in Type 1 Diabetes Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Undergo type 1 diabetes.~* To practice a moderate-vigorous exercise during 1h, 5 days or more/week before onset and continuing practicing for 2 more years for group A (active).~* To practice any or less than 5h weekly before and after onset for group S (sedentary).~* Capable to provide data and blood samples during follow up.~Exclusion Criteria:~- Not capable to provide data and blood samples required for study follow up.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Group S (sedentary) (Type: None): Group S included patients that did not perform any physical activity at the moment of onset, continuing with the same habits during the subsequent observational period.
- Group A (active) (Type: None): The inclusion criteria for group distribution took in account the principles of the American College of Sports Medicine, considering as active physical activity to practice a moderate-vigorous exercise during 1h, 5 days or more/week. In this context, a sedentary or less active person should be a person that practices any or less than 5h weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Lu AF95245 in Healthy Young Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, young, non-smoking men with a body mass index (BMI) ≥18.5 kg/m2 and ≤30 kg/m2 at the Screening Visit.~Exclusion Criteria:~* The subject has any concurrent disorder that may affect the particular target or absorption, distribution, or elimination of the IMP.~Other in- and exclusion criteria may apply

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort A: single-ascending oral dose (Type: EXPERIMENTAL): Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential
- Cohort B: (fasting/fed conditions) (Type: EXPERIMENTAL): Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.~B1: fed-fasting-fasting condition (spiked dosage)~B2: fasting-fed-fasting condition (spiked dosage)~B3: fasting-fasting-fed condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically- or cytologically- confirmed Non-Small-Cell Lung Cancer~* Stage IIIB/IV~* No prior chemotherapy~* Presence of two-dimensional measurable disease. The measurable disease should not have been irradiated.~* Absence or irradiated and stable central nervous system metastatic disease~* Life expectancy of more than 3 months~* Age ≥ 70 years.~* Performance status (WHO) \< 3~* Patients non-frail according to comprehensive geriatric assessment~* Adequate bone marrow function (Absolute neutrophil count \> 1000/mm\^3, Platelet count \> 100000/mm\^3, Hemoglobin \> 9gr/mm\^3).~* Adequate liver (Bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2mg/dl).~* Adequate cardiac function (LVEF \> 50%).~* Informed consent.~Exclusion Criteria:~* Psychiatric illness or social situation that would preclude study compliance.~* Other concurrent uncontrolled illness.~* Other invasive malignancy within the past 5 years except nonmelanoma skin cancer.~* No presence of a reliable care giver~* Other concurrent investigational agents.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): DG
- 2 (Type: EXPERIMENTAL): G

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Standardized Vascular Rehabilitation Program to Improve Patient Disease and Quality of Life

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Enrolled in the vascular rehabilitation program at The Heart Hospital Cardiac Rehabilitation Facility.~2. Female or male patients ≥18 years of age.~3. Patient must be accessible for treatment and follow-up.~4. Agrees to wear the activity tracker wrist-worn device~5. Agrees to the follow-up QOL survey schedule~6. Agrees to the follow-up ABI schedule~7. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.~Exclusion Criteria:~1. Declines participation in the study.~2. Has a life-expectancy less than 18 months.~3. Unable to complete necessary study follow-up procedures.~4. Unwilling to wear the wrist-worn activity tracker device.~5. Women who are pregnant.~6. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as:~   1. severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air~  2. home oxygen~  3. neurologic or orthopedic conditions limiting ability to appropriately comply with rehabilitation program.~  4. class III or class IV NY class congestive heart failure~7. Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vascular Rehabilitation and Follow Up (Type: OTHER): All subjects will be enrolled in a 6-12 Vascular Rehab Program (VRP) and then be followed for one year following discharge from the VRP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of PET Scans and Serotonin in Hot Flashes Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women~* 7 or more hot flashes per day for at least 3 months~* Must be able to undergo magnetic resonance (MR) and PET imaging~* Must be able to receive either paroxetine or estrogen~Exclusion Criteria:~* No treatment with hormone therapy or other medications that affect estrogen within the past 3 months~* No evidence of a currently active cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paroxetine (Type: EXPERIMENTAL): Paroxetine controlled-release (2-12.5 mg tablets, orally, every day for 4 weeks)
- Conjugated equine estrogen (Type: EXPERIMENTAL): Conjugated equine estrogen (0.625 mg tablet, orally, every day for 4 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All participants in this study will have cT1-4N0-1M0 prostate cancer or cT1-4N1-3M0 breast cancer, as clinically staged by the attending radiation oncologist following the American Joint Committee on Cancer (AJCC) 8th edition~* Non-metastatic breast or prostate cancer~* Radiation consultation for definitive treatment~* English or Spanish-speaking~Exclusion Criteria:~* Any person with major cognitive deficit or psychiatric impairment~* Any person, who with assistance by a family member or caregiver, is unable to complete a written survey

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational (survey) (Type: None): Patients complete a survey over 5-10 minutes about their understanding of radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genistein in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* Participants must have a pathologic diagnosis of prostate cancer within the past 6 months, have clinical stage T1-3 disease, PSA \>= 10, Gleason score \>= 8, and have elected to undergo radical prostatectomy; those found to have detectable circulating prostate cancer cells in the blood as detected by qRT-PCR for PSA will be eligible to proceed onto the treatment phase of the protocol; pathology slides used for diagnosis will be submitted to the SPORE tissue pathology core for review~* ECOG performance status 0-1~* Hemoglobin \> 9.0gm/dl~* Platelets \>= 100 K/uL~* ANC \> 1000/uL~* AST (SGOT)/ALT (SGPT) \< 3X upper limit of normal~* Creatinine \< 2.0 mg/dl~* Total bilirubin \< 2 mg/dl (Note: Subjects with a higher level of bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)~* Participants must agree not to take soy supplements~* Ability to understand and the willingness to sign a written informed consent document~* Willingness to take study agent for at least 2 weeks prior to radical prostatectomy~Exclusion~* History of venous thrombosis within past year~* Participants must not be receiving active therapy for neoplastic disorders (including hormone or radiation therapy for prostate cancer)~* Participants may not be receiving any other investigational agents~* Known soy intolerance~* Medical conditions that, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older;~* isolated traumatic injury to upper or lower extremity;~* alert and oriented to name, date, place; patient has a numeric pain score of 5 or higher;~* speaks English as their primary language;~* female patients are on birth control, menopausal, or are sterile (hysterectomy, tubal ligation)~Exclusion Criteria:~* injury isolated to a finger or toe;~* previous nasal or sinus surgery; chronic nasal problem;~* acute nasal problem (ie epistaxis, upper respiratory infection, sinusitis);~* pregnant; prisoner; allergy to sufentanil, fentanyl, or alfentanil; history of analgesic abuse or dependency;~* presence of other painful injuries; systolic Blood Pressure less than 100 mm Hg;~* patient seems or is confused or has a head injury; room air oxygenation less than 95%;~* patient has chronic obstructive pulmonary disease, severe asthma, oxygen-dependent pulmonary disease;~* impaired hepatic or renal function (obtained clinically or by history);~* weight more than 230 lbs (100 kg);~* alcohol or drug intoxication (per patient admission or clinical assessment of physician);~* elderly (\> 70 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal sufentanil, pain relief (Type: EXPERIMENTAL): Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EBUS-Miniprobes Sampling for Peripheral Lung Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting a peripheral lung lesion having given their approval~Exclusion Criteria:~* Lung lesion who according to ct Scan has a greater diameter lesser than 10 mm~* Ground glass lesion~* Lesion that are suspected to be a bronchopneumonia~* Contra-indication for endoscopic exam ( uncontrolled hypoxia, hypercapnia, sympotmatic bronchial hyperreactivity, recent myocardial infarction, heart failure)~* contra-indication for a transbronchial biopsy ( coagulapathy iatrogenic or not, recent uptake of anitaggregant medicines)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient with peripheral lung lesion (Type: EXPERIMENTAL): Patient presenting a peripheral lung lesion seen at Ct-scan but invisible at simple endoscopy.~Intervention : trans bronchial biopsy guided by echo-endoscopic miniprobes.~Intervention: If first intervention doesn't give a diagnosis we get cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues